Study summary
A bispecific antibody alone delayed relapse, but did not clearly extend life in the US analysis
What was tested
Epcoritamab alone, against standard chemo-immunotherapy, for DLBCL that relapsed after at least one earlier treatment, in people not eligible for stem cell transplant.
What they found
- Time before progression was longer with epcoritamab (hazard ratio 0.74); 2-year progression-free survival was 30% vs 13%.
- Complete response was more common (38% vs 26%).
- Overall survival was not significantly different in the analysis the FDA requires, though a later adjusted analysis favored epcoritamab.
What it means
Shows real activity, but the mixed survival result means its regulatory path in the US is unsettled.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.